Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy
- 5 September 2023
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (11) , 1300-1312
Abstract
Solid organ transplant (SOT) recipients receive immunosuppressive drugs (ISDs) and are susceptible to developing severe COVID-19. Here, we analyze the Spike-specific T-cell response after 3 doses of mRNA vaccine in a group of SOT patients (n = 136) treated with different ISDs. We demonstrate that a combination of a calcineurin inhibitor (CNI), mycophenolate mofetil (MMF), and prednisone (Pred) treatment regimen strongly suppressed the mRNA vaccine-induced Spike-specific cellular response. Such defects have clinical consequences because the magnitude of vaccine-induced Spike-specific T cells was directly proportional to the ability of SOT patients to rapidly clear SARS-CoV-2 after breakthrough infection. To then compensate for the T-cell defects induced by immunosuppressive treatment and to develop an alternative therapeutic strategy for SOT patients, we describe production of 6 distinct SARS-CoV-2 epitope-specific ISD-resistant T-cell receptor (TCR)-T cells engineered using the mRNA electroporation method with reactivity minimally affected by mutations occurring in Beta, Delta, Gamma, and Omicron variants. This strategy with transient expression characteristics marks an improvement in the immunotherapeutic field and provides an attractive and novel therapeutic possibility for immunosuppressed COVID-19 patients.Keywords
All Related Versions
Funding Information
- Ministry of Health -Singapore (MOH-StaR17Nov-001)
- Agency for Science, Technology and Research (SC35/22-805100, ACCL/19-GAP064-R20H-H)
- Ministry of Education - Singapore
This publication has 46 references indexed in Scilit:
- Immunosuppression following organ transplantation. Part 1: mechanisms and immunosuppressive agentsBritish Journal of Nursing, 2018
- Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infectionJournal of Clinical Investigation, 2017
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patientJournal of Hepatology, 2015
- Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive ImmunotherapyAmerican Journal of Transplantation, 2013
- A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B VirusMolecular Therapy Nucleic Acids, 2013
- Virus–drug interactions—molecular insight into immunosuppression and HCVNature Reviews Gastroenterology & Hepatology, 2012
- Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantationBlood, 2010
- Generation of Epstein-Barr virus–specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Blood, 2009
- Ex Vivo Selection and Expansion of Cells Based on Expression of a Mutated Inosine Monophosphate Dehydrogenase 2 after HIV Vector Transduction: Effects on Lymphocytes, Monocytes, and CD34+ Stem CellsMolecular Therapy, 2006
- Infusion of autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replicationBlood, 2002